

Support FY2024 DOD Peer Reviewed Breast Cancer Research Program (BCRP) Appropriations

*This is a Programmatic Request that will require online submission. No financial disclosures are required.

[Click Here to Sign On](#)

Dear Colleague:

In 2024, an estimated 297,790 new cases of invasive breast cancer will be diagnosed in women, 2,800 cases diagnosed in men, and an additional 55,720 cases of ductal carcinoma in situ (DCIS) will be diagnosed in women. Breast cancer is the second leading cause of cancer death for women in the United States after lung cancer. It is estimated that this year, 43,250 women and 530 men will die of breast cancer. Female active-duty Service members have a 20-40% higher incidence rate of breast cancer than the general public. The incident rate of breast cancer for active-duty women is seven times higher than the average incident rate of fifteen other cancer types across all Service Members.

While some progress has been made to end this disease, much work remains. As a nation, we must continue to commit to changing these statistics. The Department of Defense Peer Reviewed Breast Cancer Research Program (DOD BCRP) is a critical tool in this effort.

Since its inception, the DOD BCRP has established itself as an innovative, competitive, and accountable medical research program. The groundbreaking science performed through the program is changing the face of biomedical research. The BCRP is streamlined and efficient.

A recent GAO report on the program found that Program “obligated nearly 100 percent of its CDMRP appropriations, prioritizes and assesses biomedical research investments through effective program and project management, and coordinates with NIH and VA for research program planning and project selection and leverages shared data to identify potential overlap.”

[\(https://cdmrp.army.mil/pubs/press/2022/CDMRP_gao.aspx\)](https://cdmrp.army.mil/pubs/press/2022/CDMRP_gao.aspx)

The program can quickly respond to current scientific advances and fill gaps by focusing on traditionally underfunded research. It involves consumer advocates in all aspects of the process - both the peer review and programmatic review levels - which allows for funding decisions based on the concerns and needs of patients and the medical community.

Last year, nearly 200 U.S. Representatives supported our bipartisan effort to continue funding this worthy program. This year, we again ask that you sign the letter to the Defense Appropriations Subcommittee supporting robust funding for FY2024.

Please contact Niko Keddy (Niko.Keddy@mail.house.gov) in Congressman Garbarino’s office or Julie Jochem (Julie.Jochem@mail.house.gov) in Congresswoman Sherrill’s office with any questions.

Sincerely,

Andrew R. Garbarino
Member of Congress

Mikie Sherrill
Member of Congress

Vern Buchanan
Member of Congress

James P. McGovern
Member of Congress